Drug Profile
GRC 15300
Alternative Names: GRC 17173; GRC15300; SAR 292833Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Glenmark Pharmaceuticals Ltd
- Developer Glenmark Pharmaceuticals Ltd; Sanofi
- Class Analgesics
- Mechanism of Action TRPV3 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Musculoskeletal pain; Neuropathic pain; Skin disorders; Urinary incontinence
Most Recent Events
- 31 May 2013 Sanofi completes the phase II Alchemilla trial in Neuropathic pain in USA, Czech Republic, Hungary, Poland, Russia, Slovakia & Ukraine (NCT01463397)
- 05 Mar 2012 Phase-II clinical trials in Neuropathic pain in Czech Republic (PO)
- 05 Mar 2012 Phase-II clinical trials in Neuropathic pain in Hungary (PO)